Yukiguni Maitake Company Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Minami-Uonuma Japan (1982)
Status: No NME R&D (1982)

Organization Overview

First Clinical Trial
2010
NCT01099917
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

YUKIGUNI COMPANY

Active Ingredients

Drugs in Phase 2 Trials (1)

maitake mushroom extract (1 trial)

Drugs in Phase 1 Trials (3)

azacitidine (vidaza) (1 trial)

grifola frondosa (1 trial)

lenalidomide (revlimid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4